Related Experiment Videos

Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes

Chiara Cuccurullo1, Annalisa Iezzi, Maria Luigia Fazia

  • 1Atherosclerosis, Hypertension and Dyslipidemia Unit, G.d'Annunzio University of Chieti-Pescara, Italy.

Arteriosclerosis, Thrombosis, and Vascular Biology
|October 14, 2006
PubMed
Abstract

Insights

Simvastatin reduces plaque rupture risk by inhibiting Receptor for Advanced Glycation End Products (RAGE) expression. This statin therapy may stabilize atherosclerotic plaques in diabetic patients.

Area of Science:

  • Cardiovascular Research
  • Diabetology
  • Pharmacology

Background:

  • Receptor for Advanced Glycation End Products (RAGE) is implicated in atherosclerotic plaque rupture in diabetic patients.
  • RAGE can be upregulated independently of glucose levels via myeloperoxidase (MPO)-dependent advanced glycation end product (AGE) generation.
  • The potential for pharmacological modulation of this glucose-independent RAGE generation is unknown.

Purpose of the Study:

  • To investigate the effect of simvastatin on Receptor for Advanced Glycation End Products (RAGE) expression.
  • To assess simvastatin's impact on RAGE-dependent plaque-destabilizing genes in human atherosclerotic plaques.

Main Methods:

  • Randomized trial of 70 type 2 diabetic patients with carotid stenosis receiving simvastatin or diet alone for 4 months.
  • Analysis of plaque expression of MPO, AGEs, RAGE, inflammatory markers, matrix metalloproteinases (MMPs), lipids, and collagen.
  • Immunohistochemistry, Western blot, and zymography were employed.

Main Results:

  • Simvastatin treatment significantly reduced plaque expression of MPO, AGEs, RAGE, NF-kappaB, COX-2, mPGES-1, MMP-2, and MMP-9.
  • Reduced gelatinolytic activity and increased collagen content were observed in the simvastatin group.
  • Simvastatin's inhibition of RAGE in plaque macrophages was reversible by in vitro AGEs addition.

Conclusions:

  • Simvastatin inhibits plaque RAGE expression, likely by reducing MPO-dependent AGE generation.
  • This mechanism may contribute to plaque stabilization by downregulating PGE2-dependent MMPs.
  • Simvastatin offers a potential therapeutic strategy for stabilizing atherosclerotic plaques in diabetic individuals.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...